p53-Tumor Suppression

The vast majority of p53-regulated genes are induced in response to various stress signals and are responsible for maintaining genetic stability, DNArepair, regulation of crucial cell-cycle check points, and finally induction of apoptosis. The activity of p53 is tightly controlled by two major negative regulators including murine double minute 2 (MDM2; EC 6.3.2.19) and 4 (MDM4 or MDMX) proteins. Human MDM2 and MDMX are structurally related and contain three well-conserved domains: an N-terminal domain (responsible for p53 binding), a zinc-finger domain (function largely unknown) and a C-terminal RING domain (responsible for formation of homo- and heterodimers). Additionally, the RING domain of MDM2 confers E3 ubiquitin ligase activity. Concentration/activity of p53 is kept at low level in unstressed cells. This is accomplished by three parallel mechanisms mediated by MDM2 and/or MDMX. First, MDM2 and MDMX bind the N-terminal transactivation domain (TAD) of p53, preventing thereby its interaction with the transcription machinery and resulting in the inhibition of p53-responsive gene expression. Second, MDM2/X proteins export p53 outside the nucleus into the cytoplasm where it can no longer activate transcription. Finally, MDM2 marks p53 for proteasomal degradation[1]. Many tumors overproduce MDM2 to impair p53 function. Therefore, restoration of p53 activity by inhibiting the p53–MDM2 binding represents an attractive novel approach to cancer therapy[2].


[1] K. Zak et al. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present). Exp. Opin. Ther. Pat. 2013, 23, 425-448.
[2] B.T. Vu, L. Vassilev. Small-Molecule Inhibitors of the p53-MDM2 Interaction. Curr. Top. Microbiol. Immun. 2011, 348, 151-172.

14 Item(s)

per page
Axon ID Name Description From price
1539 AT 7519 mesylate CDK inhibitor €80.00
1966 AZD 5438 CDK inhibitor (1, 2, and 9 specific) €80.00
3228 CDK inhibitor CR8 Potent CDK inhibitor (1, 2, 5, 7, and 9 specific) €130.00
2273 LEE 011 Orally bioavailable and highly selective small-molecule inhibitor of CDK4/6 €80.00
2695 NSC 23005 sodium Novel small molecule inhibitor of INK4C (p18(INK4C) or p18) €90.00
1243 NSC 625987 CDK4 inhibitor €95.00
2052 Palbociclib isethionate Orally active cyclin-dependent kinase (CDK4/6) inhibitor €125.00
1505 PD 0332991 hydrochloride CDK4 and CDK6 inhibitor €85.00
1983 R 547 CDK inhibitor (1, 2, and 4 specific) €95.00
1530 RO 3306 CDK1 inhibitor €80.00
1776 SCH 727965 CDK inhibitor (1, 2, 5, and 9 specific) €90.00
1614 SNS 032 CDK inhibitor (2, 7 and 9 specific) €85.00
3184 SR-4835 Potent, highly selective and orally bioavailable dual CDK12/CDK13 inhibitor €130.00
3402 THZ531 First-in-class, potent, selective, covalent CDK12/CDK13 inhibitor €130.00

14 Item(s)

per page
Please wait...